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multiprotein complex involving Axin/Conductin, and theChester Beatty Laboratories
adenomatous polyposis coli-associated protein (APC)237 Fulham Road
(reviewed in Polakis, 2000). The Axin-APC complex alsoLondon SW3 6JB
binds -catenin, which is efficiently phosphorylated byUnited Kingdom
GSK3 in the presence of the Axin-APC scaffold, but
not in its absence (Ikeda et al., 1998). The Axin-APC
complex may serve a dual role of enhancing access ofSummary
GSK3 to -catenin, while restricting its access to non-
Wnt substrates. The requirement of an active Axin-APC-Glycogen synthase kinase 3 (GSK3) plays a key role
GSK3 complex for phosphorylation and consequentin insulin and Wnt signaling, phosphorylating down-
degradation of -catenin confers a tumor suppressionstream targets by default, and becoming inhibited fol-
role on this complex. Defects in APC which prevent itslowing the extracellular signaling event. The crystal
formation are associated with the most common form ofstructure of human GSK3 shows a catalytically active
hereditary colorectal cancer (Groden et al., 1991; Kinz-conformation in the absence of activation-segment
ler et al., 1991), and somatic loss of functional APC is aphosphorylation, with the sulphonate of a buffer mole-
frequent occurrence in spontaneous colorectal tumors.cule bridging the activation-segment and N-terminal
Phosphorylation of glycogen synthase (GS) by GSK3domain in the same way as the phosphate group of the
is unusual in requiring a prior phosphorylation by an-activation-segment phospho-Ser/Thr in other kinases.
other protein kinase. Thus, GSK3 only phosphorylatesThe location of this oxyanion binding site in the sub-
GS once Ser 656 of GS has been phosphorylated bystrate binding cleft indicates direct coupling of P4
casein kinase II (CK2). With GS thus “primed,” GSK3phosphate-primed substrate binding and catalytic ac-
will sequentially phosphorylate Ser 652, Ser 648, Sertivation, explains the ability of GSK3 to processively
644, and Ser 640 in a carboxy-terminal to amino-terminalhyperphosphorylate substrates with Ser/Thr pentad-
direction, with each subsequent phosphorylation de-repeats, and suggests a mechanism for autoinhibition
pendent on prior phosphorylation of the P4 positionin which the phosphorylated N terminus binds as a
(Fiol et al., 1988, 1990; Wang and Roach, 1993). A similarcompetitive pseudosubstrate with phospho-Ser 9 oc-
process of sequentially primed phosphorylation is sug-cupying the P4 site.
gested by the periodicity of the phosphorylation sites
(Ser 45, Thr 41, Ser 37, Ser 33, and Ser 29) in the mainIntroduction
Wnt target -catenin (Polakis, 1999). The kinase provid-
ing the priming phosphorylation at Ser 45 is unknown.Glycogen synthase kinase 3 (GSK3) is a Ser/Thr pro-
Efficient phosphorylation of Wnt targets is different fromtein kinase with key roles in transduction of regulatory
phosphorylation of insulin targets in requiring formationand proliferative signals arising at the cell membrane.
of a -catenin–APC–Axin–GSK3 complex (Hart et al.,
Unlike many protein kinases involved in signal transduc-
1998; Ikeda et al., 1998, 2000), and is sensitive to inhibi-
tion, GSK3 is active in the absence of the external
tion by GBP/FRAT proteins and fragments thereof (Farr
signal and becomes inhibited in response to signals et al., 2000; Li et al., 1999; Thomas et al., 1999; Yost et
from the membrane-bound receptor. In insulin signaling, al., 1998). A requirement for priming phosphorylation of
GSK3 phosphorylates (and thereby inhibits) glycogen substrates has also been reported for casein kinase I
synthase, the translation initiation factor eIF2B, and the (CK1) (Flotow et al., 1990), but here the priming position
C/EBP transcription factor (Plyte et al., 1992; Ross et is located three residues to the N-terminal side of the
al., 1999). Insulin binding to the extracellular domains target Ser/Thr. We have now determined the crystal
of the receptor activates a phosphorylation cascade structure of human GSK3, expressed in insect cells,
(Cohen, 1999), resulting in inhibitory phosphorylation of at 2.8 A˚. The structure is devoid of activation segment
GSK3 by PKB/Akt (Cross et al., 1995) with consequent phosphorylation, but is nonetheless in an activated con-
hypophosphorylation and activation of the downstream formation stabilized by the sulphonate group of a buffer
targets. In Wnt signaling, GSK3 phosphorylates -cat- molecule bound in the substrate binding cleft. Analysis
enin, promoting its ubiquitination and subsequent de- of the structure and comparison with other protein ki-
struction (Aberle et al., 1997) so that -catenin levels are nase structures suggests a mechanism of catalytic acti-
minimized. Binding of Wnt glycopeptide to the Frizzled vation coupled to binding of phosphorylated substrates,
receptor inhibits GSK3 via Dishevelled, allowing in- serendipitously mimicked by the bound buffer. This ex-
creased -catenin levels with consequent up-regulation plains the requirement of GSK3 for phosphorylation
“priming” of substrates and its ability to processively
hyperphosphorylate substrates such as glycogen syn-3 Correspondence: laurence@icr.ac.uk
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Figure 1. Structure of Human GSK3
(A) Stereo pair secondary structure cartoon of human glycogen synthase kinase 3 colored blue-red from the visible N terminus at residue
35 to the visible C terminus at residue 384. The orthogonal  barrel formed by the N-terminal domain is on the left. All molecular graphics
were generated using Robert Esnouf’s adaptation (Bobscript) of Molscript (Kraulis, 1991) and Raster3D (Merrit and Murphy, 1994), except for
Figures 3A and 6B, which were generated with GRASP (Nicholls et al., 1993).
(B) As (A), but with the view rotated by 90 around the horizontal.
thase and -catenin, and suggests a mechanism for (94–104) topologically equivalent to the C helix originally
defined in the structure of cAMP-dependent protein ki-phosphorylation-dependent autoinhibition of GSK3
following phosphorylation by PKB/Akt. nase (Knighton et al., 1991). This helix is shorter than in
other kinases, consisting of only two turns. The N-terminal
domain connects to the remainder of the protein via anResults and Discussion
helix (138–149) extending from the end of the 7th strand.
The core of the -helical domain (152–342) has a similarThe structure of GSK3 conforms to the consensus ob-
served for “activation-segment” protein kinases, con- topology to the equivalent region in the mitogen acti-
vated protein (MAP) kinases such as ERK2 and p38sisting of an amino-terminal -sheet domain, coupled to
a carboxy-terminal -helical domain. Although crystals (Wang et al., 1997; Zhang et al., 1994). The major differ-
ences are the absence of the second helix in the hairpinwere grown from full-length human GSK3 (420 residue-
sprotease-cleavable His-tag), clear electron density is segment from 276–293, where GSK3 more closely re-
sembles the cyclin-dependent kinase fold (DeBondt etonly evident for the 351 residues from Lys 35 to Ser
386, and the segments of polypeptide preceding 35 and al., 1993). Beyond residue 342, GSK3 departs substan-
tially from the MAPK fold, with residues 342–386 formingfollowing 386 are disordered in these crystals. The visi-
ble N-terminal domain (35–134) of GSK3 consists of a a series of short helices and loops packed against the
long helix (155–175) in the large domain, rather thanseven-stranded  sheet curved over on itself to form a
closed orthogonal  barrel (Figure 1). This is different snaking back to rejoin the N terminus as in the MAPKs.
At the C-terminal extremity of the visible polypeptide,to the equivalent domains in related Ser/Thr kinases,
and more closely resembles the N termini of protein the two molecules in the asymmetric unit make different
lattice contacts and the structures diverge, with the seg-tyrosine kinases such as insulin receptor kinase (Hub-
bard et al., 1994) and members of the Src-kinase family ment from Pro379 to Arg383 forming a turn of helix in
one molecule, while having an extended conformation(Sicheri et al., 1997; Xu et al., 1997). The 5th and 6th
strands of the barrel are connected by a short  helix in the other.
Structure of GSK3
723
Conformation of Activation Loop phosphorylation of Thr 183 into activation. Remarkably,
and Catalytic Groups in GSK3, the same interaction and consequent align-
The catalytic activity of protein kinases depends upon ment of the catalytic apparatus is achieved by an exoge-
the correct juxtaposition of the catalytic groups contrib- nous anion, occupying an equivalent position to the
uting to the transfer of the -phosphate group from ATP covalently attached phosphate of activated ERK2,
to a serine, threonine, or tyrosine side chain of the pro- which cross-links the activation segment to the basic
tein substrate. A second factor is the accessibility and cluster by nonbonded polar interactions. The shape and
correct positioning of the groups forming the substrate size of the electron density and the nature of the proxi-
peptide binding site, which provide affinity and specific- mal groups suggest that the bound anion is a phosphate
ity for the substrate (Johnson et al., 1996). In many ki- or sulfate. However, neither of these ions was explicitly
nases, these two requirements are simultaneously con- present in the buffers used to purify and crystallize hu-
tingent upon the conformation of an “activation segment” man GSK3 (see Experimental Procedures). HEPES
which contains residues that are themselves subject ([4-(2-hydroxyethyl)-1-piperazineethane sulphonate)
to phosphorylation. In the dephosphorylated state, the was used in buffers throughout the purification and
conformation of the activation segment disfavors kinase would be 10 mM (with a protein concentration of 
activity. Phosphorylation promotes a conformation of 0.1 mM) in the crystallization experiments. HEPES pos-
the activation segment in which the catalytic and sub- sesses a sulphonate group whose chemistry is consis-
strate binding sites are correctly formed, leading to a tent with the requirements of the site. Furthermore, a
substantial increase (1000-fold for MAP kinases) in second strong electron density feature is present adja-
activity. Thus, phosphorylation of the activation seg- cent to the oxyanion site, which corresponds well in size
ment provides a means by which the activity of one and position to the piperazineethane moiety of a HEPES
protein kinase can be regulated by a second protein molecule bound to the enzyme (Figure 2A).
kinase, allowing the familiar signal transduction cas-
cades. A Substrate-Coupled Activation Mechanism
In the MAP kinases, two sites of phosphorylation exist In MAP kinases, cAMP-dependent kinases, and cyclin-
within the activation segment, Thr 183 and Tyr 185 in the dependent kinases, a significant component of activa-
sequence 180-GFLTEYVATR-188 (Robbins et al., 1993). tion comes from the interaction of basic residues in the
The residue corresponding to Tyr 185 in the activation N-terminal domain and catalytic loop with a phosphate
segment sequence in GSK3 (210-GEPNVSYICSR-220), covalently attached to the activation segment (Canaga-
Tyr 216, has been found to be phosphorylated in GSK3 rajah et al., 1997; Knighton et al., 1991; Russo et al.,
(Hughes et al., 1993). The residue corresponding to Thr 1996). In phosphorylase kinase (PhK), which is not acti-
183 of ERK2 is Val 214 in GSK3 and although the adja- vated by phosphorylation (Cox and Johnson, 1992), the
cent residue (215) is serine, its phosphorylation has not equivalent of Thr 183 in ERK2 is glutamate, whose nega-
been reported. Within the GSK3 crystals themselves, tive charge provides a constitutive activating interaction
there is no indication of the strong electron density fea- with the basic cluster (Owen et al., 1995). In some (but
ture that would be expected if Tyr 216 were phosphory-
not all) crystal structures of casein kinase 1 (CK1) (Long-
lated (Figure 2A). Despite the absence of any phosphory-
necker et al., 1996; Xu et al., 1995), oxyanions were
lation, the GSK3 activation segment has a very similar
bound close to the activation segment in a similar fash-
conformation to the activation segment in the doubly
ion to the oxyanion we observe in GSK3, interactingphosphorylated active form of ERK2 (Canagarajah et
with two basic residues from the underlying structure.al., 1997), but is significantly different from that in the
However, CK1 is not activated by phosphorylation andunphosphorylated ERK2 structure (Zhang et al., 1994)
only two basic residues, both from the C-terminal do-(Figure 2B). Furthermore, the arrangement of residues
main, interact with the anion. In contrast, in GSK3 (asin GSK3 implicated in the catalytic mechanism of phos-
in ERK2 and cAPK/PKA), three basic residues, includingphoryl-transfer is superimposable on the arrangement
one from the C helix in the N-terminal  domain, con-of the equivalent residues in other structures of acti-
verge at this site. In the absence of an anion, the intensevated Ser/Thr protein kinases (Canagarajah et al., 1997;
positive potential generated by this cluster of basic sideLowe et al., 1997) (Figure 2C). Taken together, these data
chains could not be adequately neutralized, and mostsuggest that unlike MAP kinase or cAMP-dependent
significantly, the interaction with Arg 96 from the N-terminalkinases, GSK3 can achieve a catalytically active con-
domain, which positions the catalytic residues in theirformation in the absence of activation segment phos-
active conformation, would be hard to maintain (Figurephorylation.
3). The crystal structure of Chk1, a Ser/Thr kinase in-While there is no electron density for phosphates co-
volved in cell-cycle checkpoint regulation (Chen et al.,valently attached to the activation segment in GSK3,
2000), also contained a phosphate ion bound near towe observed a very strong electron density feature in
the activation segment, but this does not interact withdifference Fourier maps ( 6) within hydrogen bonding
the N-terminal domain and plays no role in activationdistance of the peptide main chain at Asn 213 to Val
segment conformation, which was unchanged in crys-214. This feature is also close to the positively charged
tals grown in the absence of oxyanion.side chain head groups of Arg 96, Arg180, and Lys 205,
In vivo, the site occupied by the sulphonate of HEPESwhich converge at this site, suggesting that this feature
could be occupied by inorganic phosphate present inrepresents an anionic species. In activated ERK2, the
the cell so that, other regulatory factors aside, GSK3equivalent residues (Arg 68, Arg 146, and Arg 170) form
would be constitutively present in a catalytically compe-the binding site for the phosphate of pThr 183 and via
that interaction, translate the signal represented by the tent state. However, the unusual substrate preference
Cell
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Figure 2. Activation Loop and Active Site Conformation
(A) Stereo pair showing electron density for the activation segment from residues 212–219 and the bound HEPES buffer (HEP). Gold “chicken-
wire” is from a 2FoFc Fourier map contoured at 1.0; blue chicken-wire is from an FoFc map contoured at 3.0. In both cases, calculated
amplitudes and phases are from the refined structure of the protein only. No electron density consistent with phosphorylation of Tyr 216 is
visible in either map.
(B) Comparison of the activation-segment conformation of GSK3 (blue) with the equivalent region of unphosphorylated inactive ERK2 (yellow,
right) and diphosphorylated active ERK2 (red, left).
(C) Stereo pair showing superposition of the side chains of the catalytic residues of activated ERK2 (yellow), phosphorylase kinase (magenta),
and GSK3 (CPK colors). Only the secondary structure of GSK3 is shown.
of GSK3 suggests an alternative and much more inter- (Lowe et al., 1997) identifies those GSK3 residues that
constitute the binding subsites for the phosphorylatableesting role for this anion binding site. Analysis of sites
phosphorylated by GSK3 (see Table 2) suggests a pref- Ser/Thr in a substrate peptide (site P 0), and for adjacent
substrate residues N-terminal (sites Pn) and C-termi-erence for sequences of the type: Ser/Thr–X–X–X–Ser/
Thr, where the C-terminal serine or threonine is already nal (sites Pn) to that. As in PhK, the P3, P1, P1,
and P3 substrate residues would be bound to exposedphosphorylated (Fiol et al., 1988, 1990; Wang and
Roach, 1993), so that prior phosphorylation of the n4th surface sites on GSK3, and would exert relatively little
sequence specificity. The P2 binding site in GSK3residue facilitates phosphorylation of the nth residue.
Superposition of GSK3with the PhK substrate complex (formed by Ser 219, Arg220, and Tyr 221) is more
Structure of GSK3
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Figure 3. Oxyanion Binding Site
(A) Stereo pair of solvent-accessible surface
of GSK3 colored according to the electro-
static potential: red, negative; blue, positive.
The intense positive patch generated by the
basic side chains of Arg 96, Arg 180, and
Lys 205 is indicated, as is the location of the
catalytic aspartate 181 and Arg 220, which
could interact with a phosphorylated Tyr 216.
(B) Position of the bound HEPES molecule
relative to the overall structure of GSK3. The
negatively charged sulphonate group of
HEPES is close to the positive patch (see [A])
generated by Arg 180 and Lys 205 from the
large domain and Arg 96 on the C helix of
the N-terminal domain (blue side chains). The
side chains of the catalytic residues Asp 181
and Asp 200 are shown in red.
(C) Detail of the hydrogen bonding network
involving the sulphonate of HEPES, the side
chains of Arg 96, Arg 180, and Lys 205, and
the main chain of Asn 213 and Val 214 in the
activation segment.
crowded than the equivalent site in PhK (Thr 186, Pro interactions with a substrate. Immediately beyond the
P3 binding site in GSK3 is the position of the strong187, and Ser 188), and would disfavor bulky substrate
side chains. The position and conformation of the phos- electron density feature, which we attribute to a HEPES
molecule with its sulphonate group bound to the sidephorylatable substrate serine in PhK is determined by
a stretch of antiparallel  sheet formed between the chains of Arg 96, Arg180, and Lys 205, and to the peptide
NH of Val 214 in the activation segment. The P4 residuesubstrate from P0 to P3 and the activation segment
of the enzyme from Val 183 to Thr 186. In GSK3, the of a substrate peptide, bound to GSK3 in a similar
conformation to that seen in PhK, could be readily ac-conformation of the corresponding part of the activation
segment, Tyr 216 to Ser 219, would facilitate similar commodated at this position such that the phosphate
Cell
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activity regardless of the state of Thr 183 (Robbins etTable 1. Crystallographic Statistics
al., 1993; Zhang et al., 1995). Phosphorylation of Tyr 216
Data Collection All data (outer shell)
in GSK3 has been described (Hughes et al., 1993), and
Rmerge 0.074 (0.323) a requirement for tyrosine phosphorylation observed in
I/(I) 8.4 (2.3) vivo (Murai et al., 1996). However, unlike MAP kinases,
Completeness (%) 99.9 (99.9)
GSK3 devoid of Tyr 216 phosphorylation is capableMultiplicity 5.6 (5.6)
of achieving an activated configuration of its catalyticNo. Unique Reflections 33,985 (4,883)
residues and a conformation of the activation segment
Structure Refinement
receptive to substrate binding, suggesting that phos-
No. of Atoms (Protein) 5,567 phorylation of Tyr 216 is not essential for activity. Con-
No. of Atoms (All) 5,786 sistent with this, mutation of Tyr 216 to phenylalanine
Resolution Range 35–2.8 A˚
did not impair GSK3 activity in Wnt signaling, nor signif-Rcryst 0.220
icantly alter the kinase activity of GSK3 on myelin basicRfree 0.254
protein (Itoh et al., 1995). Furthermore, saturating tyro-
sine phosphorylation in vitro by ZAK1, the only specific
GSK3-tyrosine kinase so far identified (Kim et al., 1999)group of a phosphoserine or phosphothreonine could
only doubled GSK3 kinase activity. This low level ofbind in the same site as the sulphonate of HEPES (Fig-
activation compared to MAP kinases suggests that theure 4A).
effect of Tyr 216 phosphorylation on GSK3 is subtle.Although we have not observed the structure of
In the conformation observed in the GSK3 structure,GSK3 in an inactive conformation, it seems likely that,
the unphosphorylated Tyr 216 side-chain has a gaucheas in ERK2 or cAPK, the convergence of three basic
conformation, directed down toward the bottom of theresidues required for the active conformation can only
peptide binding cleft. In this orientation, it crowds thebe achieved with the counterbalancing negative charge
substrate binding site and impedes access to the puta-provided by an oxyanion. Thus, the the side chains of
tive P4 phosphate binding site. At the equivalent posi-Arg 96, Arg180, Lys 205, and the peptide NH of Val
tion in activated ERK2, the side chain of pTyr 185 has214 in GSK3 provide a specific binding site for the
an anti conformation which directs it out of the substratephosphate groups of P4 phosphate-primed sub-
binding site so that the phosphate group interacts withstrates, whose binding then stabilizes the active confor-
Arg 189 and Arg 192. A comparable conformation for amation of the enzyme, directly coupling substrate speci-
pTyr 216 would be possible in GSK3, with the tyrosylficity to enzymatic activity.
phosphate group interacting with Arg 220 and Arg 223,
the topological equivalent of 189 and 192 in ERK2, andA Role for Tyrosine Phosphorylation
allowing full access to the P4 binding site (Figure 4B).in Modulating GSK3 Activity
While phosphorylation would force the “up” conforma-One important difference between GSK3 and PhK oc-
tion for Tyr 216, there is no inherent barrier to this confor-curs in the vicinity of the P3 substrate binding site,
mation in its absence, so that although Tyr 216 phos-which is provided by the side chain and main chain of
phorylation would facilitate substrate binding, it may notVal 183 in PhK. The corresponding residues in GSK3
be an absolute requirement in situations where otherand in ERK2 are tyrosines (Tyr 216 and Tyr 185), whose
factors serve to enhance the affinity of GSK3 for aphosphorylation is implicated in kinase activation. In
ERK2, phosphorylation of Tyr 185 is essential for kinase substrate.
Table 2. Sites Phosphorylated by GSK3
Protein Sequence Residues
Glycogen synthase ASVPPS 639–644
Glycogen synthase PSPSLS 643–648
Glycogen synthase LSRHSS 647–652
Glycogen synthase SSPHQS 651–656
Elongation initiation factor 2B 	 subunit DSRAGS 539–544
cAMP-responsive element binding protein (CREB) LSRRPS 128–133
CCAAT/enhancer binding protein  (C/EBP) PTPPPT 225–230
CCAAT/enhancer binding protein  (C/EBP) PTPVPS 229–234
Microtubule associated protein Tau KSPVVS 395–400
Microtubule associated protein Tau VSGDTS 399–404
-catenin QSYLDS 28–34
-catenin DSGIHS 32–37
-catenin HSGATT 36–41
-catenin TTTAPS 40–45
Axin TSANDS 321–326
Axin DSEQQS 325–330
Dd-STATa SSPLPS 130–135
Dd-STATa PSSPLS 125–130
Cyclin D1 CTPTDV 285–290
The site to be phosphorylated is in bold, while the P4 residue whose phosphorylation “primes” GSK3 activity is underlined. All sequence
numbers are for the mammalian protein except Dd-STATa which are for the Dictystelium protein.
Structure of GSK3
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Figure 4. Phospho-Substrate Binding Model and Tyr 216 Conformation
(A) Model of substrate binding to GSK3 based on structural alignment with the structure of a phosphorylase kinase–peptide substrate
complex (PDB code 2PHK). The modeled substrate corresponds to residues 642–648 of human glycogen synthase (-642-PPSPSLS-648),
whose phosphorylation at Ser 644 by GSK3 requires a “priming” phosphoserine at 648. The position of the serine to be phosphorylated is
indicated at P(0) and that of the priming phospho-serine at P(4). The phosphate at P(4) occupies the same position as the sulphonate of
the bound HEPES. The rotamer of Tyr 216 was changed to an anti conformation to eliminate steric clashes.
(B) Comparison of the conformations of the activation segment tyrosine in GSK3 (left) and the phosphorylated equivalent tyrosine in activated
ERK2. Simple rotation of the side chain of Tyr 216 in GSK3 around the C-C bond brings it into the same position as the pTyr 185 in ERK2,
and, if phosphorylated, would be stabilized in that conformation by interaction with Arg 220 and Arg 223.
Mechanism of Inhibition by SER 9 Phosphorylation (Figure 5A); however, clear dose-dependent inhibition
of GSK3 kinase activity was observed with the identicalInsulin signaling promotes phosphorylation of Ser 9 in
GSK3 by PKB/Akt (Cross et al., 1995), with consequent peptide when Ser 9 was phosphorylated (Figure 5B). An
unrelated peptide containing a phosphoserine had noinhibition of GSK3. The structural basis for this has not
been defined, but could involve one of two mechanisms. effect on GSK3 activity at comparable concentrations
(Figure 5C), showing that the inhibition was not simplyPhosphorylation at Ser 9 could be an allosteric effect,
promoting a catalytically inactive conformation, in an mediated by a phosphate group, but dependent on the
sequence context of the phospho-serine and thereforeinverse version of the more commonly observed phos-
phorylation-dependent activation found in many protein specific. Detailed kinetic analysis (Figure 5D) clearly
showed competitive inhibition by the phosphorylated Nkinases. Alternatively, the phosphorylated N-terminal re-
gion might be directly autoinhibitory, blocking access (3–12) peptide, with a Ki of  700 
M. While this inhibi-
tion, although specific, is relatively weak in these inter-to the active site and/or substrate binding cleft, but only
when phosphorylated. To distinguish between these molecular in vitro assays, in vivo, the peptide is cova-
lently attached to the enzyme so that binding is anmechanisms, we analyzed GSK3 activity in the pres-
ence of a peptide based on its N-terminal segment intramolecular reaction with a very large effective con-
centration.(3–12), including the phosphorylatable Ser 9. No inhibi-
tion was observed with the unphosphorylated peptide The requirement for phosphorylation and competition
Cell
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Figure 5. Competitive Inhibition by Phosphorylated N Terminus
(A) Phosphorylation of GSM peptide (Km  70 
M) by GSK3 in vitro in the presence of a peptide derived from residues 3–12 of GSK3. The
activity is undiminished even in the presence of 5-fold excess of GSK3-N(3-12) peptide. All points in (A), (B), and (C) are averages of two
measurements.
(B) As (A), but with varying concentrations of GSK3-N(3-12) peptide in which Ser 9 is phosphorylated, resulting in clear inhibition of substrate
phosphorylation.
(C) As (A) but with varying concentrations of an unrelated peptide containing a phosphoserine. As in (A), no inhibition of GSM phosphorylation
by GSK3 is observed.
(D) Double-reciprocal (Lineweaver-Burk) plot of reaction velocity versus substrate concentration in the presence of increasing concentrations
of the Ser 9 phosphorylated GSK3-N(3-12) peptide. All points are means of three measurements. The progressive increase in slope indicates
competitive inhibition, with a Ki for the peptide of  700 
M.
(E) Inhibition of GSK3 activity via direct competitive autoinhibition by the N terminus binding in the substrate binding site with the phosphory-
lated Ser 9 occupying the P(4) phospho-priming binding site. The segment connecting the bound N terminus and the visible N terminus of
GSK3 in the present crystal is shown as a dotted magenta line, whose detailed path is purely hypothetical.
Structure of GSK3
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Figure 6. GSK3 Dimer Interactions
(A) Secondary structure cartoon of GSK3 crystal dimer, viewed approximately down the noncrystallographic diad axis. Monomers are color-
ramped blue-red from N to C terminus on the left and by chain on the right.
(B) Stereo pair of solvent accessible surface for the two monomers calculated separately and colored by chain.
(C) Comparison between the dimer interactions in the vicinity of the activation segment from one monomer (color ramped), with Asp 260, Ser
261, and Val 262 from the other monomer (LEFT), and the same region in the substrate-complex modeled on the structure of the phosphorylase
kinase–substrate complex 2PHK (right). The side chain of Ser 261 in the dimer occupies approximately the same site as the phosphorylatable
serine in the substrate peptide, close to the side chains of the catalytic residues Asp 181 and Asp 200 (in red).
with substrate peptide suggests a mechanism for autoin- inhibition could occur in cis, with 24 residues available
to bridge the  42 A˚ between the visible N terminus inhibition in which the phosphorylated N-terminal segment
binds in the substrate binding cleft as a pseudo-primed the present GSK3 structure (Ser 35), and pSer9 at the
C terminus of the bound inhibitory peptide (Figure 5E).substrate, with the phosphorylated Ser occupying the
P4 phospho-Ser/Thr binding site. With the N-terminal Residues 1–34 lie outside the canonical protein kinase
fold, and are completely disordered in this presentsegment thus positioned, the P0 binding site, in which
the phospho-accepting serine or threonine of a real sub- GSK3 crystal structure, so that this model for autoin-
hibition remains to be verified structurally.strate would be located, would be occupied by Pro 5.
A proline at this position would be readily accommo-
dated, as its side chain has a similar volume to serine or Dimer Structure
GSK3 crystallized as a dimer, with the monomers re-threonine, and can conform to the main chain substrate
conformation observed at this position in other Ser/Thr lated by a noncrystallographic diad (Figures 6A and 6B).
Dimers have been observed in crystals of other proteinkinase-peptide complexes. With an inhibitory Ser 9-phos-
phorylated N-terminal segment bound in that way, auto- kinases, including ERK2 (Canagarajah et al., 1997) and
Cell
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may have functional significance (Cobb and Goldsmith, strates with P4 priming phosphorylation. Together
2000). However, the GSK3 dimer more closely resembles with our observation that peptides derived from the N
the head-to-tail interaction observed in phosphorylase terminus of GSK3 competitively inhibit its kinase activ-
kinase (Lowe et al., 1997). The main sites of dimeric ity, this suggests a model for the mechanism of inhibition
interaction are residues Asp 260 to Val 263 at the N of GSK3 following phosphorylation of Ser 9 by PKB/Akt
terminus of an  helix (262–273) from one monomer, in response to the insulin signal. At least one apparent
which interacts with Tyr 216 to Arg 220 at the end of the GSK3 substrate, Cyclin D1, is phosphorylated at a loca-
activation segment in the other. Direct polar interactions tion in which the P4 residue is valine (Diehl et al., 1998),
are limited to an ion pair between Asp 260 and Arg 220, suggesting that unprimed phosphorylation can occur
and main chain to main chain hydrogen bonds between under some circumstances. GSK3 is specifically inhib-
the peptide carbonyls of Asp 260 and Val 263 with the ited by lithium ions (Stambolic et al., 1996), and this is
peptide nitrogens of Arg 220 and Tyr 216, respectively. a source of considerable medical interest, as lithium is
The hydrophobic face of the side chain of Tyr 216 inter- a valuable agent in the treatment of depressive disease
acts with a hydrophobic patch formed by Ile 228, Phe (Williams and Harwood, 2000). Even at much higher res-
229, Gly 262, Val 263, and Leu 266 from the other mono- olution than we have so far obtained, it will be very
mer. Despite the overall shape complementarity at the difficult to identify the lithium binding site as it is virtually
interface, there are few other direct contacts, although invisible to X-rays.
several solvent-bridged interactions are evident. Over- The major questions remaining in the molecular biol-
all, dimer formation buries  2358 A˚2 of accessible sur- ogy of GSK3 relate to its ability to operate in two dis-
face, which is slightly more than in the PhK dimer (Lowe tinct signaling pathways with no apparent cross-talk.
et al., 1997). The positions occupied in one monomer Insulation of the Wnt and insulin signals is achieved
by the segment Asp 260–Ser 261–Val 262 from the other by recruitment of GSK3 into a multiprotein complex
coincides approximately with the expected location of containing Axin and APC, which facilitates phosphoryla-
the P1, P0, and P1 residues of a substrate peptide. tion of -catenin, and allows GSK3 activity to be regu-
Productive binding of even a small peptide substrate is lated by Dishevelled in response to Wnt binding to the
thus precluded by the observed dimer. However, within Frizzled receptor. Structural studies of the specific inter-
the dimer, both the position and conformation of Ser actions between GSK3 and the components of the
261 are close to those expected for the phosphorylata- Wnt-signalosome hold the key to a full understanding
ble serine of a productively bound substrate peptide of this system.
(Figure 6C). This raises the possibility that these dimer
interactions are on the path to a productive trans-phos-
Experimental Proceduresphorylation of Ser 261, although no such phosphoryla-
tion has been reported so far.
Cloning, Expression, and Purification
The presence of an intimate dimer prompts consider- Human GSK3 was expressed in the Bac-to-Bac baculovirus ex-
ation of its biological relevance. With GSK3, we can pression system (Life Technologies). The hGSK3 gene was ampli-
detect dimer formation in solution by cross-linking, at fied by PCR from an existing clone, and inserted as an NcoI/XhoI
fragment into the donor plasmid, pFASTBAC HTa. This constructconcentrations as low as 5 
M, suggesting that dimer-
prepends a His6-affinity purification tag and a cleavage site for theization is not an artifact of crystallization. While the pres-
TEV protease to the N terminus of the GSK3 peptide sequence.ent data does not allow a definitive assessment of its
The construct was sequenced to ensure no errors had been intro-functional relevance, the structure of the GSK3 dimer
duced. An apparent His-Leu mutation was found at codon 350 in
at least allows us to predict several properties that would the PCR product, but was also found to be leucine in the original
bear upon a putative biological role. First, the substrate template cDNA. In sequences from other species, this position is a
binding site is obstructed by dimerization, so that the conserved leucine/hydrophobic residue, and is buried in the crystal
structure. We believe that the original assignment of histidine fordimer would be inactive in heterophosphorylation, but
this codon in the deposited peptide sequence (Swissprotpotentially active in homophosphorylation in trans. As
KG3B_HUMAN) is wrong and that leucine is correct.a corollary, N-terminal autoinhibition in the manner we
The recombinant pFASTBAC HTa plasmid was transformed intosuggest and dimerization would be mutually exclusive.
DH10Bac cells for transposition of the GSK3 gene into the bacmid
Second, as the side chain of Tyr 216 in the “down” according to manufacturer’s instructions, and transposition was
conformation participates in the dimer interface, its confrmed by PCR. Bacmids were transfected into Sf9 cells (2.0 
phosphorylation and consequent rotation to the up con- 105 to 2.0 106 cells/ml) in SF900II media supplemented with penicil-
lin and streptomycin, and grown in shaker flasks at 27C, 150 rpm.,formation would be antagonistic, at least in part, to di-
according to manufacturer’s protocols (Life Technologies). Virusmerization. Dimerization of GSK3 in vivo could be regu-
was amplified using a multiplicity of infection (MOI) of 0.1, a celllated by interaction with other proteins in the APC-Axin
density of 2.0  106 and a 3 day incubation. Expression was withscaffolded Wnt-regulated complex. In support of that
an MOI of 2, a cell density of 2.0  106 and a 3 day incubation. Cells
idea, we have observed disruption of GSK3 dimeriza- were harvested by centrifugation at 1000  g for 5 min, and cell
tion in cross-linking experiments, on addition of other pellets were stored at 80C. Cells were lysed by thawing, hand
components of the Wnt signaling complex (in prepara- homogenizing in 50 mM HEPES-NaOH and 50 mM NaCl (pH 7.2)
supplemented with protease inhibitors, and sonicating for 1 min. Thetion), but the biological significance of this remains to
clarified supernatant was applied to an SP-Sepharose (Pharmacia)be determined.
column (2.6  15 cm), and the protein was eluted using a gradient
of 0–1 M NaCl in 50mM HEPES-NaOH (pH 7.2). Fractions wereConclusions pooled, pH adjusted to 7.6, and applied to a Talon (Clontech)
column (1.6  2.5 cm), which was washed with 50 mM HEPES-
The structure of GSK3 presented here provides a satis- NaOH, 300 mM NaCl and 5 mM Im-HCl (pH 7.6), and the protein
eluted with 50 mM HEPES-NaOH, 300 mM NaCl, and 200 mM Im-HClfactory explanation for the preference of GSK3 for sub-
Structure of GSK3
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(pH 7.0). One mM EDTA was added, and the protein was concen- on kinase assays, Maggie Yeo for practical assistance, and Adrian
Harwood, David Barford, and Chris Marshall for helpful discussion.trated and applied to a Superdex 200 column (Pharmacia, 26/60)
developed with 20 mM HEPES-NaOH, 150 mM NaCl, 1 mM EDTA, This work was supported by the Cancer Research Campaign (T.C.D.)
and the Institute of Cancer Research Structural Biology Initiativeand 1 mM DTT (pH 7.2). Fractions were applied to a Mono-S (Phar-
macia) 1 ml column, and eluted with a gradient of 0.15–1 M NaCl (L.H.P.).
in 20 mM HEPES-NaOH, and 1 mM DTT (pH 7.2). The protein was
concentrated to 10 mg/ml using a 0.5 ml Microcon centrifugal Received November 21, 2000; revised May 3, 2001.
concentrator (Amicon), and MgCl2 added to a final concentration of
2 mM. Purified GSK3 was stored at 80C.
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